|Bid||56.36 x 1400|
|Ask||56.37 x 800|
|Day's Range||55.38 - 56.58|
|52 Week Range||52.04 - 77.03|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||8.99|
|Earnings Date||Nov 06, 2020|
|Forward Dividend & Yield||2.00 (3.54%)|
|Ex-Dividend Date||Oct 21, 2020|
|1y Target Est||78.68|
For the seventh consecutive year, Aetna®, a CVS Health® company (NYSE: CVS), announced its 2021 Medicare Advantage Prescription Drug (MAPD) plans outpace the Medicare Advantage industry in the percentage of members in plans rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services (CMS). Star Ratings data for 2021 contracts show 83 percent of Aetna MAPD members are currently enrolled in 4 Star-rated plans or higher, compared to 77 percent for the industry.1
As part of CVS Health's (NYSE: CVS) ongoing effort to increase access to COVID-19 testing and help slow the spread of the virus, the company today announced plans to expand COVID-19 testing services currently offered at select CVS Pharmacy locations to include rapid-result testing at nearly 1,000 sites by the end of the year.
Walmart Inc, Walgreens Boots Alliance Inc, CVS Health Corp and Rite Aid Corp have told Reuters demand for flu shots at their U.S. pharmacies is up sharply - in some cases double from last year - as people try to protect themselves from influenza in the midst of a worsening COVID-19 pandemic.The pharmacies are giving millions more flu shots than they have in past years, filling a gap from COVID-19 wary consumers who are avoiding the doctor's office. U.S. public health officials have been urging Americans for months to inoculate themselves against the flu, which kills about 60,000 people a year, warning of a potential "twindemic" of influenza and the novel coronavirus that could overwhelm hospitals this winter.